healthcare

LeMaitre Vascular will present at five major healthcare investment conferences in March 2026, engaging with institutional investors and analysts about corporate strategy and growth opportunities.

Abbott maintains 54-year dividend streak with 10% EPS growth projected for 2026, despite near-term diagnostic headwinds and manufacturing challenges offsetting strategic acquisitions and FDA approvals.

Johnson & Johnson maintains Dividend King status with 63 consecutive years of dividend increases, offering stable income through its diversified healthcare business and AAA credit rating.

Medtronic offers defensive stability through 48 years of dividend increases, essential medical devices, and consistent profitability across economic cycles.

Ardent Health shares plunged 33% after revealing a $43 million revenue adjustment due to overstated receivables. A securities fraud lawsuit was filed over misleading accounting disclosures.

Major M&A wave reshapes industries: Danaher acquires Masimo for $9.9B, Devon completes $21.4B energy merger, while Starboard pressures TripAdvisor toward sale.

Averin Capital raises $250M SPAC targeting tech and healthcare acquisitions. Securities begin Nasdaq trading February 19, 2026.

Capital rotation from mega-cap tech stocks reveals value opportunities in beverage, healthcare, and energy sectors. Keurig Dr Pepper, Cooper Companies, and Matador Resources offer attractive valuations and growth potential.

Turner Syndrome treatment market projected to double to $3.67B by 2033, driven by diagnostic innovation, increased awareness, and improved access to therapies globally.

Lumexa Imaging leadership will present at three major healthcare investment conferences in March 2026, providing investors direct access during sector growth.

Axogen will present at three major healthcare conferences in March 2026, conducting investor meetings and showcasing its business case to institutional investors and analysts.